Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + paclitaxel
- Development stage
- Phase 3
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Combination therapy of **anlotinib** (a multitargeted small molecule tyrosine kinase inhibitor with antiangiogenic and antiproliferative activity) and **paclitaxel** (a microtubule stabilizer and widely used cytotoxic chemotherapeutic, often in the albumin-bound, nab-paclitaxel, formulation). Anlotinib inhibits multiple targets, including VEGFR, PDGFR, and FGFR, suppressing tumor angiogenesis and proliferation, while paclitaxel interferes with microtubule disassembly, inhibiting cell division. This combination is under investigation primarily for treatment of advanced or stage IV **non-small cell lung cancer (NSCLC)**, and in some protocols, for other advanced cancers such as esophageal squamous cell carcinoma (ESCC) and small-cell lung cancer (SCLC) with brain metastases. Clinical data show the combination improves response rates, disease control, immune function, and quality of life in advanced NSCLC, and has a manageable safety profile[1][2][3][4].
- Other names
- anlotinib plus paclitaxelanlotinib + albumin-bound paclitaxelanlotinib + nab-paclitaxel
02
Targets
FGFR (Fibroblast growth factor receptor)PDGFR (PDGFR family)VEGFR (VEGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR (FGFR family)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on anlotinib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + paclitaxel.